Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important?

Expert Rev Anticancer Ther. 2024 May 13:1-4. doi: 10.1080/14737140.2024.2354772. Online ahead of print.
No abstract available

Keywords: PD-L1; Recurrent/metastatic head and neck cancer; cetuximab; chemotherapy; combined positive score; pembrolizumab.

Publication types

  • Editorial